C4 Therapeutics Stock Short Interest Rises to 38.09%

C4 Therapeutics short interest was 38.09% of the float on October 30th, according to new data we received from Benzinga. Short interest totaled 46,580,600 shares, which was an increase of 9.03% from October 15th.

It is estimated that it would take 15.14 days for short sellers to buy back their shares, with current trading volumes.

C4 Therapeutics Hedge Fund Activity

We have seen 94 institutional investors add shares of C4 Therapeutics stock to their portfolio, and 62 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• BLACKROCK, INC. added 5,848,192 shares (+285.5%) to their portfolio in Q2 2026, for an estimated $27,311,056
• SQUADRON CAPITAL MANAGEMENT LLC added 4,950,000 shares (+220.0%) to their portfolio in Q2 2026, for an estimated $23,116,500
• JPMORGAN CHASE & CO added 4,747,424 shares (+inf%) to their portfolio in Q2 2026, for an estimated $22,170,470
• IKARIAN CAPITAL, LLC added 2,433,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $11,362,110
• D. E. SHAW & CO., INC. added 1,688,110 shares (+3192.4%) to their portfolio in Q2 2026, for an estimated $7,883,473
• PATIENT SQUARE CAPITAL LP removed 1,608,815 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $5,357,353
• HIGHVISTA STRATEGIES LLC added 1,348,136 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,295,795

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Check out the Investivoq API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.